AC Immune Will Regain All Global Rights To Crenezumab And Semorinemab Following Termination Of The Collaboration Agreements With Genentech, a part of Roche
Portfolio Pulse from Benzinga Newsdesk
AC Immune SA will regain all global rights to its Alzheimer's treatment candidates, crenezumab and semorinemab, after the termination of its collaboration agreements with Genentech, a member of the Roche group. This follows Genentech's decision to return the rights to AC Immune, which could impact the future development and potential commercialization of these drugs.
January 22, 2024 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
AC Immune regains full rights to Alzheimer's drugs after Genentech ends collaboration. This could lead to new partnership opportunities or the need for additional funding for development.
While regaining rights can be positive, suggesting control and flexibility for AC Immune, it also means the loss of a major partner in Genentech, which could lead to uncertainties regarding the continuation of development and funding for the drug candidates. The impact is neutral short term as the market digests the implications.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Roche's Genentech returns rights of Alzheimer's drugs to AC Immune, indicating a shift in focus or a strategic decision to discontinue collaboration on these treatments.
The termination of the collaboration with AC Immune may reflect a strategic decision by Roche's Genentech to reallocate resources or change its focus in the Alzheimer's treatment landscape. The short-term impact is neutral as the market evaluates the reasons behind this decision and its implications for Roche's pipeline.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60